Financial Review: Corium International (CORI) versus Its Rivals

Corium International (NASDAQ: CORI) is one of 103 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Corium International to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.

Volatility and Risk

Corium International has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Corium International’s competitors have a beta of 0.92, meaning that their average stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Corium International and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corium International -149.99% -482.64% -62.37%
Corium International Competitors -2,466.98% -68.60% -7.96%

Insider and Institutional Ownership

89.1% of Corium International shares are owned by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 46.5% of Corium International shares are owned by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Corium International and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corium International 0 0 6 0 3.00
Corium International Competitors 959 3858 6884 183 2.53

Corium International currently has a consensus target price of $13.00, indicating a potential upside of 8.79%. As a group, “Pharmaceuticals” companies have a potential upside of 18.91%. Given Corium International’s competitors higher probable upside, analysts plainly believe Corium International has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Corium International and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Corium International $31.86 million -$47.79 million -7.16
Corium International Competitors $8.31 billion $1.11 billion 152.14

Corium International’s competitors have higher revenue and earnings than Corium International. Corium International is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Corium International competitors beat Corium International on 7 of the 13 factors compared.

Corium International Company Profile

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply